CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) (such as PD-1/PD-L1 antibodies) represent a breakthrough by potentiating T cell-mediated anti-tumor immunity, yet their efficacy is confined to roughly 20–30% of patients [2].